GAMMA Investing LLC Buys 1,213 Shares of Mesoblast Limited (NASDAQ:MESO)

GAMMA Investing LLC raised its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 22.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,711 shares of the company’s stock after purchasing an additional 1,213 shares during the period. GAMMA Investing LLC’s holdings in Mesoblast were worth $133,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of MESO. Signaturefd LLC lifted its position in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after buying an additional 3,099 shares in the last quarter. Perkins Coie Trust Co lifted its holdings in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares in the last quarter. Rathbones Group PLC bought a new position in shares of Mesoblast in the second quarter worth approximately $95,000. XTX Topco Ltd purchased a new stake in shares of Mesoblast in the second quarter worth $103,000. Finally, Creative Planning purchased a new stake in shares of Mesoblast in the third quarter worth $147,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MESO shares. Piper Sandler lifted their target price on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Mesoblast currently has a consensus rating of “Hold” and an average price target of $13.50.

Mesoblast Trading Down 4.0 %

Shares of NASDAQ:MESO opened at $17.18 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a fifty day moving average price of $12.90 and a 200 day moving average price of $9.33. Mesoblast Limited has a fifty-two week low of $1.61 and a fifty-two week high of $22.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.